Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
17 February, 2019 22:07 IST
Zydus Cadila gets final nod for Carbamazepine ER tablets
Source: IRIS | 11 Feb, 2019, 10.57AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the USFDA to market Carbamazepine Extended-Release Tablets USP (US RLD - Tegretol XR), 100 mg, 200 mg, and 400 mg. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Carbamazepine is an anticonvulsant agent. It works by reducing excessive nerve signals in the brain and restoring the normal balance of nerve activity. This medication is used to treat certain types of seizures (partial, generalized tonic-clonic, mixed) and certain types of nerve pain (trigeminal and glossopharyngeal neuralgia).

The group now has 248 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 2.9, or 0.9%, to trade at Rs 324.80. The total volume of shares traded was 15,465 at the BSE (9.59 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Sensex, Nifty end flat; Sun Pharma, Tata Steel fall 3% each - 15-Feb-2019 17:05
Lupin launches Clobazam oral suspension - 15-Feb-2019 16:37
Sensex falls near 90 points; Nifty trades at 10,703 - 15-Feb-2019 10:40
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer